Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments

Jaehyun Ahn; Christopher Shin; Yeo Song Kim; Jae Sung Park; Sin Soo Jeun; Stephen Ahn

doi:10.14791/btrt.2022.0010

Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments

Jaehyun Ahn
, Christopher Shin
, Yeo Song Kim
, Jae Sung Park
, Sin Soo Jeun
, Stephen Ahn

Department of Neurosurgery

The Catholic University of Korea, College of Medicine
Catholic Univ. of Korea Coll. Med.

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vaccines for recurrent or newly diagnosed glioblastoma patients, several studies did not at all agree with the existence of CMV in glioblastoma cells. In this review, we summarized the conflicting results and issues about the detection of CMV in glioblastoma or glioma patients. We also provided the clinical data of published and unpublished clinical trials using CMV-specific immunotherapy for glioblastomas.

Original language	English
Pages (from-to)	135-143
Number of pages	9
Journal	Brain Tumor Research and Treatment
Volume	10
Issue number	3
DOIs	https://doi.org/10.14791/btrt.2022.0010
State	Published - Jul 2022

Bibliographical note

Publisher Copyright:
© 2022 The Korean Brain Tumor Society, The Korean Society for NeuroOncology, and The Korean Society for Pediatric Neuro-Oncology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adoptive cell transfer
Cancer vaccines
Cytomegalovirus
Glioblastoma
Immunotherapy

Access to Document

10.14791/btrt.2022.0010

Cite this

@article{d218ac73ea1f4631bcaf9ca08a688f7b,

title = "Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments",

abstract = "Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vaccines for recurrent or newly diagnosed glioblastoma patients, several studies did not at all agree with the existence of CMV in glioblastoma cells. In this review, we summarized the conflicting results and issues about the detection of CMV in glioblastoma or glioma patients. We also provided the clinical data of published and unpublished clinical trials using CMV-specific immunotherapy for glioblastomas.",

keywords = "Adoptive cell transfer, Cancer vaccines, Cytomegalovirus, Glioblastoma, Immunotherapy",

author = "Jaehyun Ahn and Christopher Shin and Kim, \{Yeo Song\} and Park, \{Jae Sung\} and Jeun, \{Sin Soo\} and Stephen Ahn",

note = "Publisher Copyright: {\textcopyright} 2022 The Korean Brain Tumor Society, The Korean Society for NeuroOncology, and The Korean Society for Pediatric Neuro-Oncology.",

year = "2022",

month = jul,

doi = "10.14791/btrt.2022.0010",

language = "English",

volume = "10",

pages = "135--143",

journal = "Brain Tumor Research and Treatment",

issn = "2288-2405",

publisher = "The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology",

number = "3",

}

TY - JOUR

T1 - Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments

AU - Ahn, Jaehyun

AU - Shin, Christopher

AU - Kim, Yeo Song

AU - Park, Jae Sung

AU - Jeun, Sin Soo

AU - Ahn, Stephen

PY - 2022/7

Y1 - 2022/7

N2 - Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vaccines for recurrent or newly diagnosed glioblastoma patients, several studies did not at all agree with the existence of CMV in glioblastoma cells. In this review, we summarized the conflicting results and issues about the detection of CMV in glioblastoma or glioma patients. We also provided the clinical data of published and unpublished clinical trials using CMV-specific immunotherapy for glioblastomas.

AB - Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vaccines for recurrent or newly diagnosed glioblastoma patients, several studies did not at all agree with the existence of CMV in glioblastoma cells. In this review, we summarized the conflicting results and issues about the detection of CMV in glioblastoma or glioma patients. We also provided the clinical data of published and unpublished clinical trials using CMV-specific immunotherapy for glioblastomas.

KW - Adoptive cell transfer

KW - Cancer vaccines

KW - Cytomegalovirus

KW - Glioblastoma

KW - Immunotherapy

UR - https://www.scopus.com/pages/publications/105007690574

U2 - 10.14791/btrt.2022.0010

DO - 10.14791/btrt.2022.0010

M3 - Review article

AN - SCOPUS:105007690574

SN - 2288-2405

VL - 10

SP - 135

EP - 143

JO - Brain Tumor Research and Treatment

JF - Brain Tumor Research and Treatment

IS - 3

ER -

Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this